You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

5389 Results
Drug
Other Name(s): Tecvayli®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2025
Drug
Other Name(s): Columvi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Oct 2025
Document
Sep 2024
Document
Sep 2024
Document
Sep 2024
Document
Oct 2024
Document
Oct 2024
Document
Oct 2024
Drug
Other Name(s): Asparlas®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2025
Document
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    cabozantinib – For the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma, in combination with nivolumab, according to clinical criteria
New Drug Funding Program
    Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
nivolumab,
cabozantinib (tablet)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Completely Resectable Stage III or IV Melanoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025

Pages